Traws Pharma shares surge 14.05% after-hours as Phase 2 ratutrelvir study completes with fewer adverse events and no viral rebounds versus PAXLOVID.

Traws Pharma surged 14.05% in after-hours trading following the announcement of positive Phase 2 clinical results for ratutrelvir, its oral COVID-19 treatment, and progress in its tivoxavir marboxil influenza program. The study showed ratutrelvir outperformed PAXLOVID® with fewer adverse events, no viral rebounds, and faster symptom resolution, while also addressing a critical unmet need for PAXLOVID®-ineligible patients. Additionally, the company advanced tivoxavir marboxil as a potential once-monthly influenza prophylactic, with a 28-day protection profile and a planned human challenge study in June 2026. These developments highlight Traws’ potential to capture significant market opportunities in respiratory antiviral therapies, driving investor optimism.